Literature DB >> 35386737

Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.

Johan Clukers1, Maarten Lanclus2, Dennis Belmans3, Cedric Van Holsbeke3, Wilfried De Backer1, Dharshan Vummidi4, Paul Cronin4, Ben R Lavon3, Jan De Backer2, Dinesh Khanna5.   

Abstract

Introduction: Systemic sclerosis-associated interstitial lung disease accounts for up to 20% of mortality in these patients and has a highly variable prognosis. Functional respiratory imaging, a quantitative computed tomography imaging technique which allows mapping of regional information, can provide a detailed view of lung structures. It thereby shows potential to better characterize this disease. Purpose: To evaluate the use of functional respiratory imaging quantitative computed tomography in systemic sclerosis-associated interstitial lung disease staging, as well as the relationship between short-term changes in pulmonary function tests and functional respiratory imaging quantitative computed tomography with respect to disease severity. Materials and methods: An observational cohort of 35 patients with systemic sclerosis was retrospectively studied by comparing serial pulmonary function tests and in- and expiratory high-resolution computed tomography over 1.5-year interval. After classification into moderate to severe lung disease and limited lung disease (using a hybrid method integrating quantitative computed tomography and pulmonary function tests), post hoc analysis was performed using mixed-effects models and estimated marginal means in terms of functional respiratory imaging parameters.
Results: At follow-up, relative mean forced vital capacity percentage change was not significantly different in the limited (6.37%; N = 13; p = 0.053) and moderate to severe disease (-3.54%; N = 16; p = 0.102) groups, respectively. Specific airway resistance decreased from baseline for both groups. (Least square mean changes -25.11% predicted (p = 0.006) and -14.02% predicted (p = 0.001) for limited and moderate to severe diseases.) In contrast to limited disease from baseline, specific airway radius increased in moderate to severe disease by 8.57% predicted (p = 0.011) with decline of lower lobe volumes of 2.97% predicted (p = 0.031).
Conclusion: Functional respiratory imaging is able to differentiate moderate to severe disease versus limited disease and to detect disease progression in systemic sclerosis.
© The Author(s) 2021.

Entities:  

Keywords:  Interstitial lung disease; computer-assisted image analysis; multidetector-row computed tomography; systemic scleroderma

Year:  2021        PMID: 35386737      PMCID: PMC8892932          DOI: 10.1177/2397198320985377

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  33 in total

1.  Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis.

Authors:  Alarico Ariani; Mario Silva; Valeria Seletti; Elena Bravi; Marta Saracco; Simone Parisi; Fabio De Gennaro; Luca Idolazzi; Paola Caramaschi; Camilla Benini; Flavio Cesare Bodini; Carlo Alberto Scirè; Greta Carrara; Federica Lumetti; Veronica Alfieri; Elisa Bonati; Gianluca Lucchini; Marina Aiello; Daniele Santilli; Flavio Mozzani; Davide Imberti; Emanuele Michieletti; Eugenio Arrigoni; Giovanni Delsante; Raffaele Pellerito; Enrico Fusaro; Alfredo Chetta; Nicola Sverzellati
Journal:  Rheumatology (Oxford)       Date:  2017-06-01       Impact factor: 7.580

2.  Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Authors:  Nicole S Goh; Rachel K Hoyles; Christopher P Denton; David M Hansell; Elisabetta A Renzoni; Toby M Maher; Andrew G Nicholson; Athol U Wells
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

3.  Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.

Authors:  Margaret L Salisbury; David A Lynch; Edwin J R van Beek; Ella A Kazerooni; Junfeng Guo; Meng Xia; Susan Murray; Kevin J Anstrom; Eric Yow; Fernando J Martinez; Eric A Hoffman; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-04-01       Impact factor: 21.405

Review 4.  Systemic sclerosis.

Authors:  Christopher P Denton; Dinesh Khanna
Journal:  Lancet       Date:  2017-04-13       Impact factor: 79.321

5.  Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

Authors:  Demosthenes Bouros; Athol U Wells; Andrew G Nicholson; Thomas V Colby; Vlasis Polychronopoulos; Panos Pantelidis; Patricia L Haslam; Dimitris A Vassilakis; Carol M Black; Roland M du Bois
Journal:  Am J Respir Crit Care Med       Date:  2002-06-15       Impact factor: 21.405

6.  Interstitial lung disease in systemic sclerosis: a simple staging system.

Authors:  Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

7.  The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.

Authors:  Jan De Backer; Wim Vos; Samir Vinchurkar; Cedric Van Holsbeke; Gianluigi Poli; Rita Claes; Rodrigo Salgado; Wilfried De Backer
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-07-08       Impact factor: 2.849

Review 8.  Systemic sclerosis-associated interstitial lung disease.

Authors:  Apostolos Perelas; Richard M Silver; Andrea V Arrossi; Kristin B Highland
Journal:  Lancet Respir Med       Date:  2020-02-20       Impact factor: 30.700

9.  Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up.

Authors:  Stephen M Humphries; Kunihiro Yagihashi; Jason Huckleberry; Byung-Hak Rho; Joyce D Schroeder; Matthew Strand; Marvin I Schwarz; Kevin R Flaherty; Ella A Kazerooni; Edwin J R van Beek; David A Lynch
Journal:  Radiology       Date:  2017-05-10       Impact factor: 11.105

10.  Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.

Authors:  J Clukers; M Lanclus; B Mignot; C Van Holsbeke; J Roseman; S Porter; E Gorina; E Kouchakji; K E Lipson; W De Backer; J De Backer
Journal:  Respir Res       Date:  2018-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.